{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T21:38:21Z","timestamp":1780522701103,"version":"3.54.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T00:00:00Z","timestamp":1626048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T00:00:00Z","timestamp":1626048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["DARU J Pharm Sci"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s40199-021-00404-w","type":"journal-article","created":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T20:02:47Z","timestamp":1626120167000},"page":"501-506","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Durable complete response to pembrolizumab in microsatellite stable colorectal cancer"],"prefix":"10.1007","volume":"29","author":[{"given":"Marzieh","family":"Gomar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoumeh","family":"Najafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Aghili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Cozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4611-8859","authenticated-orcid":false,"given":"Amin","family":"Jahanbakhshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,12]]},"reference":[{"issue":"2","key":"404_CR1","doi-asserted-by":"publisher","first-page":"142","DOI":"10.6004\/jnccn.2017.0016","volume":"15","author":"J Gong","year":"2017","unstructured":"Gong J, Wang C, Lee PP, et al. Response to PD-1 blockade in microsatellite stable metastatic colorectal cancer harboring a POLE mutation. J Natl Compr Canc Netw. 2017;15(2):142\u20137. https:\/\/doi.org\/10.6004\/jnccn.2017.0016.","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"404_CR2","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","volume":"16","author":"K Ganesh","year":"2019","unstructured":"Ganesh K, Stadler ZK, Cercek A, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16(6):361\u201375. https:\/\/doi.org\/10.1038\/s41575-019-0126-x.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"404_CR3","doi-asserted-by":"publisher","unstructured":"Le DT, Uram JN, Wang H, et al. Programmed death-1 blockade in mismatch repair deficient colorectal cancer. Journal of Clinical Oncology. 2016;34(15_suppl):103\u2013103. https:\/\/doi.org\/10.1200\/JCO.2016.34.15_suppl.103.","DOI":"10.1200\/JCO.2016.34.15_suppl.103"},{"issue":"9","key":"404_CR4","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","volume":"18","author":"MJ Overman","year":"2017","unstructured":"Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182\u201391.","journal-title":"Lancet Oncol"},{"issue":"12","key":"404_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189848","volume":"12","author":"BH O'Neil","year":"2017","unstructured":"O\u2019Neil BH, Wallmark JM, Lorente D, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. PLoS ONE. 2017;12(12): e0189848. https:\/\/doi.org\/10.1371\/journal.pone.0189848.","journal-title":"PLoS ONE"},{"key":"404_CR6","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/158038","volume":"2015","author":"J Jacobs","year":"2015","unstructured":"Jacobs J, Smits E, Lardon F, et al. Immune checkpoint modulation in colorectal cancer: what\u2019s new and what to expect. J Immunol Res. 2015;2015: 158038. https:\/\/doi.org\/10.1155\/2015\/158038.","journal-title":"J Immunol Res"},{"issue":"6230","key":"404_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69\u201374. https:\/\/doi.org\/10.1126\/science.aaa4971.","journal-title":"Science"},{"key":"404_CR8","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3389\/fonc.2019.00396","volume":"9","author":"AF Oliveira","year":"2019","unstructured":"Oliveira AF, Bretes L, Furtado I. Review of PD-1\/PD-L1 inhibitors in metastatic dMMR\/MSI-H colorectal cancer. Front Oncol. 2019;9:396. https:\/\/doi.org\/10.3389\/fonc.2019.00396.","journal-title":"Front Oncol"},{"key":"404_CR9","doi-asserted-by":"publisher","first-page":"9037217","DOI":"10.1155\/2020\/9037217[publishedOnlineFirst:2020\/02\/25]","volume":"2020","author":"M Kreidieh","year":"2020","unstructured":"Kreidieh M, Mukherji D, Temraz S, et al. Expanding the scope of immunotherapy in colorectal cancer: current clinical approaches and future directions. Biomed Res Int. 2020;2020:9037217. https:\/\/doi.org\/10.1155\/2020\/9037217[publishedOnlineFirst:2020\/02\/25].","journal-title":"Biomed Res Int"},{"issue":"26","key":"404_CR10","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509\u201320.","journal-title":"N Engl J Med"},{"key":"404_CR11","doi-asserted-by":"publisher","unstructured":"Lee JJ, Sun W, Bahary N, et al. Phase 2 study of pembrolizumab in combination with azacitidine in subjects with metastatic colorectal cancer: Journal of Clinical Oncology. 2017;35(15_suppl):3054\u20133054. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.3054.","DOI":"10.1200\/JCO.2017.35.15_suppl.3054"},{"key":"404_CR12","doi-asserted-by":"publisher","unstructured":"Bendell JC, Kim TW, Goh BC, et al. Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC). Journal of Clinical Oncology\u00a034, no.\u00a015_suppl (May 20, 2016) 3502\u20133502. https:\/\/doi.org\/10.1200\/JCO.2016.34.15_suppl.3502.","DOI":"10.1200\/JCO.2016.34.15_suppl.3502"},{"key":"404_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.16.00005","volume":"1","author":"S Sorscher","year":"2017","unstructured":"Sorscher S, Resnick J, Goodman M. First case report of a dramatic radiographic response to a checkpoint inhibitor in a patient with proficient mismatch repair gene expressing metastatic colorectal cancer. JCO Precis Oncol. 2017;1:1\u20134. https:\/\/doi.org\/10.1200\/PO.16.00005.","journal-title":"JCO Precis Oncol"},{"key":"404_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.573547[publishedOnlineFirst:2021\/03\/26]","volume":"11","author":"G Cui","year":"2021","unstructured":"Cui G. The mechanisms leading to distinct responses to PD-1\/PD-L1 blockades in colorectal cancers with different MSI statuses. Front Oncol. 2021;11: 573547. https:\/\/doi.org\/10.3389\/fonc.2021.573547[publishedOnlineFirst:2021\/03\/26].","journal-title":"Front Oncol"},{"key":"404_CR15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.humpath.2017.09.019[publishedOnlineFirst:2017\/12\/07]","volume":"72","author":"G Le Flahec","year":"2018","unstructured":"Le Flahec G, Badic B, Guibourg B, et al. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells. Hum Pathol. 2018;72:135\u201343. https:\/\/doi.org\/10.1016\/j.humpath.2017.09.019[publishedOnlineFirst:2017\/12\/07].","journal-title":"Hum Pathol"}],"container-title":["DARU Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-021-00404-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40199-021-00404-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-021-00404-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T12:03:11Z","timestamp":1637236991000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40199-021-00404-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,12]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["404"],"URL":"https:\/\/doi.org\/10.1007\/s40199-021-00404-w","relation":{},"ISSN":["2008-2231"],"issn-type":[{"value":"2008-2231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,12]]},"assertion":[{"value":"20 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}